Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma

Area of Science:

• Oncology
• Immunotherapy

Background:

• Interferon (IFN) and interleukin-2 (IL-2) are active in malignant melanoma treatment but associated with significant side effects and poor compliance.
• Low-dose subcutaneous IL-2 has shown good tolerability and efficacy in renal cancer.
• Synergistic effects between low-dose IL-2 and IFN are hypothesized.

Purpose of the Study:

• To evaluate the feasibility and patient compliance of a combined recombinant IFN-alpha (rIFN-alpha) and low-dose IL-2 regimen for malignant melanoma.
• To assess the tolerability and potential efficacy of this novel combination therapy.

Main Methods:

• A regimen combining intramuscular rIFN-alpha (3 million units, 3x/week) and subcutaneous low-dose IL-2 (9 million IU, 3-5x/week) was administered for 2 weeks every 28 days.
• Fifteen heavily pretreated patients with disseminated malignant melanoma were enrolled.
• Patients self-administered therapy at home in an out-patient setting.

Main Results:

• The regimen was feasible and well-tolerated in an out-patient setting, with high patient compliance.
• No WHO grade 4 side effects were observed; grade 3 side effects (fever, asthenia) occurred in 5% of cycles.
• Mild hematologic toxicity (grade 2) was noted at higher IL-2 doses. No major responses were observed.

Conclusions:

• The studied regimen of IL-2 plus rIFN-alpha is feasible and well-tolerated in an out-patient setting.
• The regimen is unlikely to be effective as a standalone treatment for heavily pretreated malignant melanoma.
• Good patient compliance suggests potential for evaluating this combination to enhance chemotherapy outcomes.